Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement News In Brief

Executive Summary

MedPAC “Doc Fix” Offset Options Include Mandated Part D Rebates

You may also be interested in...



MedPAC's Permanent "Doc Fix" For Medicare Seeks $75 Bil. Offset From Drug Firms

The Medicare Payment Advisory Commission's draft plan seeks approximately $235 billion in offsets from a range of non-physician sources.

Part D Donut Hole Costs Drug Manufacturers $461 Million Through First Half Of 2011

The pace of those taking advantage of the 50% discount on brand drugs provided by manufacturers is accelerating as the year progresses, with 899,000 beneficiaries getting the discounts through the end of June.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel